The presence of multiple key indicators increases the probability of asthma, but spirometry is needed to establish a diagnosis.
Wheezing:
• High-pitched whistling sounds when breathing out-especially in children. A lack of wheezing and a normal chest examination do not exclude asthma 
DIAGNOSIS OF ASTHMA:
• Episodic symptoms of airway obstruction or airway hyperresponsiveness are present.
• Airway obstruction is at least partially reversible, measured by spirometry. Reversibility is determined by an increase in FEV 1 of >200 mL and > 12 percent from baseline measure after inhalation of short-acting beta2-agonist (SABA). Some studies indicate that an increase of > 10percent of the predicted FEV 1 after inhalation of a SABA may have higher likelihood of separating patients who have asthma from those who have chronic obstructive pulmonary disease (COPD).
• Alternative diagnoses are excluded. See discussion below.
Recommended methods to establish the diagnosis are:
• Detailed medical history.
• Physical examination may reveal findings that increase the probability of asthma, but the absence of these findings does not rule out asthma, because the disease is variable and signs may be absent between episodes. The examination focuses on: − upper respiratory tract (increased nasal secretion, mucosal swelling, and/or nasal polyp;
− chest (sounds of wheezing during normal breathing or prolonged phase of forced exhalation, − hyperexpansion of the thorax, use of accessory muscles, appearance of hunched shoulders, chest deformity); and − skin (atopic dermatitis, eczema). Spirometry can demonstrate obstruction and assess reversibility in patients >5 years of age. Patients' perceptions of airflow obstruction are highly variable. Spirometry is an essential objective measure to establish the diagnosis of asthma, because the medical history and physical examination are not reliable means of excluding other diagnoses or of assessing lung status. Spirometry is generally recommended, rather than measurements by a peak flow meter, due to wide variability in peak flow meters and reference values. Peak flow meters are designed for monitoring, not as diagnostic tools.
A differential diagnosis of asthma should be considered. Recurrent episodes of cough and wheezing most often are due to asthma in both children and adults; however, other significant causes of airway obstruction leading to wheeze must be considered both in the initial diagnosis and if there is no clear response to initial therapy.
Additional studies are not routinely necessary but may be useful when considering alternative diagnoses.
• Additional pulmonary function studies will help if there are questions about COPD (diffusing capacity), a restrictive defect (measures of lung volumes), or VCD (evaluation of inspiratory flow-volume loops).
• Bronchoprovocation with methacholine, histamine, cold air, or exercise challenge may be useful when asthma is suspected and spirometry is normal or near normal. For safety reasons, bronchoprovocation should be carried out only by a trained individual. A positive test is diagnostic for airway hyperresponsiveness, which is a characteristic feature of asthma but can also be present in other conditions. Thus, a positive test is consistent with asthma, but a negative test may be more helpful to rule out asthma.
• Chest x-ray may be needed to exclude other diagnoses.
• Biomarkers of inflammation are currently being evaluated for their usefulness in the diagnosis and assessment of asthma. Biomarkers include total and differential cell count and mediator assays in sputum, blood, urine, and exhaled air.
Common diagnostic challenges include the following:
• Cough variant asthma. Cough can be the principal -or only -manifestation of asthma, especially in young children. Monitoring of PEF or bronchoprovocation may be helpful. Diagnosis is confirmed by a positive response to asthma medications.
• Vocal Cord Dysfunction (VCD) can mimic asthma, but it is a distinct disorder. VCD may coexist with asthma.
Asthma medications typically do little, if anything, to relieve VCD symptoms. Variable flattening of the inspiratory flow loop on spirometry is strongly suggestive of VCD. Diagnosis of VCD is from indirect or direct vocal cord visualization during an episode, during which the abnormal adduction can be documented. VCD should be considered in difficult-to-treat, atypical asthma patients and in elite athletes who have exercise-related breathlessness unresponsive to asthma medication.
• Gastrointestinal reflux disease (GERD), obstructive pulmonary sleep apnea(OSA), and allergic bronchopulmonary aspergillosis (ABPA) may coexist with asthma and complicate diagnosis.
• Children ages 0-4 years. Diagnosis in infants and young children is challenging and is complicated by the difficulty in obtaining objective measurements of lung function in this age group. Caution is needed to avoid giving young children inappropriate prolonged asthma therapy. However, it is important to avoid underdiagnosing asthma, and thereby missing the opportunity to treat a child, by using such labels as "wheezy bronchitis," "recurrent pneumonia," or "reactive airway disease" (RAD). The chronic airway inflammatory response and structural changes that are characteristic of asthma can develop in the preschool years, and appropriate asthma treatment will reduce morbidity.
Consider referral to an asthma specialist if signs and symptoms are atypical, if there are problems with a differential diagnosis, or if additional testing is indicated.
GOAL OF THERAPY: CONTROL OF ASTHMA Reduce Impairment:
• Prevent chronic and troublesome symptoms (e.g., coughing or breathlessness in the daytime, in the night, or other exertion).
• Require infrequent use (< 2 days a week) of inhaled SABA for quick relief of symptoms (not including prevention of exercise-induced bronchospasm (EIB)).
• Maintain (near) normal pulmonary fuction.
• Maintain normal activity levels (including exercise and other physical activity and attendance at school or work).
• Meet patients' and families' expectations and satisfaction with asthma care.
Reduce Risk:
• Prevent recurrent exacerbations of asthma and minimize the need for ED visits or hospitalization.
• Prevent loss of lung function; for children, prevent reduced lung growth.
• Provide optimal pharmacotherapy with minimal or no reverse effects of therapy.
Achieving and maintaining asthma control requires four components of care: assessment and monitoring, education for partnership in care, control of environmental factors and comorbid conditions that affect asthma and medications. A stepwise approach to asthma management incorporates these four components, emphasizing that pharmacologic therapy is initiated based on asthma severity and adjusted (stepped up or down) based on the level of asthma control. Special considerations of therapeutic options within the stepwise approach may be necessary for situations such as exercise-induced bronchospasm (EIB), surgery, and pregnancy.
Four Components of Asthma Care: Component 1: Assessing and Monitoring Asthma Severity and Asthma Control
The functions of assessment and monitoring are closely linked to the concepts of severity, control, and responsiveness to treatment:
• Severity: the intrinsic intensity of the disease process. Severity is easily and directly measured in a patient who is not receiving long-term control therapy. Severity can also be measured, once asthma control is achieved, by the step of care (i.e., the amount of medication) required to maintain control. Less emphasis is being place on classifying severity and greater emphasis is placed on controlling the disease.
• Control: the degree to which manifestations of asthma are minimized by therapeutic intervention and the goals of therapy are met.
• Responsiveness: the ease with which asthma control is achieved by therapy.
Asthma severity and asthma control include the domains of current impairment and future risk.
• Impairment: frequency and intensity of symptoms and functional limitations the patient is currently experiencing or has recently experienced.
• Risk: the likelihood of either asthma exacerbations, progressive decline in lung function (or, for children, reduced lung growth), or risk of adverse effects from medication.
This distinction emphasizes the multifaceted nature of asthma and the need to consider separately asthma's current, ongoing effects on the present quality of life and functional capacity and the future risk of adverse events. The two domains may respond differentially to treatment. For example, evidence demonstrates that some patients can have adequate control of symptoms and minimal day-to-day impairment, but still be at signiifciant risk of exacerbations; these patients should be treated accordingly.
The specific measures used to access severity and control are similar: symptoms, use of SABAs for quick relief of symptoms, limitations to normal activities due to asthma, pulmonary function, and exacerbations. Multiple measures are important, because different measures assess different manifestations of the disease and may not correlate with each other.
The concepts of severity and control are used as follows for managing asthma:
• Assess severity to initiate therapy. During a patient's initial presentation, if the patient is not currently taking long-term control medication, asthma severity is assessed to guide clinical decisions for initiating the appropriate medication and other therapeutic interventions.
• Assess control to adjust therapy. Once therapy is initiated, the emphasis for clinical management thereafter is changed to the assessment of asthma control. The level of asthma control will guide decisions either to maintain or to adjust therapy (i.e., step up if necessary, step down if possible).
• For assessing a patient's overall asthma severity, once the most optimal asthma control is achieved and maintained, or for population-based evaluations or clinical research, asthma severity can be inferred by correlating the level of severity with the lowest level of treatment required to maintain control.
The emphasis for clinical management is to assess asthma severity prior to initiating therapy and then to assess asthma control for monitoring and adjusting therapy.
For the initial assessment to characterize the patient's asthma and guide decisions for initiating therapy, use information from the diagnostic evaluation to:
• Classify asthma severity.
• Identify precipitating factors for episodic symptoms (e.g., exposure at home, work, daycare, or school to inhalant allergens or irritants).
• Identify comorbid conditions that may impede asthma management (i.e., sinusitis, rhinitis, GERD, OSA, obesity, stress, or depression).
• Assess the patient's knowledge and skills for self-management.
For periodic monitoring of asthma control to guide decisions for maintaining or adjusting therapy:
• Instruct patients to monitor their asthma control in an ongoing manner. All patients should be taught how to recognize inadequate asthma control. − Either symptom or peak flow monitoring is appropriate for most patients; evidence suggests the benefits are similar. − Consider daily peak-flow monitoring for patients who have moderate or severe persistent asthma, patients who have a history of severe exacerbations, and patients who poorly perceive airway obstruction or worsening asthma.
• Monitor asthma control periodically in clinical visits, because asthma is highly variable over time and therapy may need to be adjusted (stepped up if necessary, stepped down if possible). The frequency of monitoring is a matter of clinical judgement. In general: − Schedule visits at 2 to 6 week intervals for patients who are just starting therapy or who require a step up in therapy to achieve or regain asthma control. − Schedule visits at 1 to 6 month intervals, after asthma control is achieved, to monitor whether asthma control is maintained. The interval will depend on factors such as the duration of asthma control or the level of treatment required. − Consider scheduling visits at 3 month intervals if a step down in therapy is required.
• Assess asthma control, medication technique, the written asthma action, adherence, and patient concerns at every patient visit. Use spirometry to obtain objective measures of lung function. − Perform spirometry at the following times: · Initial assessment. · After treatment is initiated and symptoms and PEF have stabilized. · During periods of progressive or prolonged loss of asthma control. · At least every 1 to 2 years; more frequently depending on response to therapy − Low FEV 1 indicates current obstruction (impairment) and risk for future exacerbations (risk). For children FEV 1 /forced vital capacity (FVC) appears to be a more sensitive measure of severity and control in the impairment domain. FEV 1 is a useful measure of risk for exacerbations, although it is emphasized that even children who have normal lung function experience exacerbations. Minimally invasive markers (called biomarkers) such as fractionated exhaled nitric oxide (FeNO) and sputum eosinophils may be useful, but biomarkers require further evaluation before they are recommended as clinical tools for routine management.
